Misguided Pricing Tactics Delay Access To Medicines, Warns NHS England
Executive Summary
Pharmaceutical companies must not delay patient access to medicine through “salami slicing” pricing strategies, says Blake Dark, commercial medicines director at NHS England.
You may also be interested in...
ABPI Exec Lauds Innovation And Access Provisions In New UK Voluntary Scheme
Speakers at a meeting in London examined the key provisions of the new voluntary pricing and access scheme, which replaced the PPRS at the beginning of January. The Pink Sheet spoke to the Association of the British Pharmaceutical Industry’s Paul Catchpole about enhanced planning for the introduction of new treatments on the national health service, and the shape of the new “commercial flexibilities” intended to allow earlier patient access to innovation.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.